Apolipoprotein C-III reduction in subjects with moderate hypertriglyceridaemia and at high cardiovascular risk
Randomised, Phase II dose-ranging study (n=114) found olezarsen (antisense oligonucleotide targeted to hepatic APOC3 mRNA to inhibit apolipoprotein C-III production) significantly reduced fasting triglycerides (up to 60% relative reduction from baseline with 50mg every 4 weeks).
Source:
European Heart Journal
SPS commentary:
The study included adults with established or at high risk of atherosclerotic cardiovascular disease, and an elevated fasting triglyceride level (2.26–5.65 mmol/L). The researchers say that olezarsen has the potential to address unmet therapeutic needs in subjects with uncontrolled triglyceride levels and CVD, demonstrating significant reductions in fasting triglyceride levels by up to 60%, with 91% achieving levels <1.7 mmol/L. However, the dose-ranging study was not powered for clinical endpoints and further studies are needed to address whether targeting apolipoprotein C-III production will reduce cardiovascular events.